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EVALUATION OF A WIRELESS HANDHELD MEDICATION MANAGEMENT
PROGRAM IN THE PREVENTION OF DRUG-DRUG INTERACTIONS
Saverno K, Malone DC
University of Arizona College of Pharmacy, Tucson, AZ, USA
OBJECTIVES: Drug-related adverse events impose a substantial burden on patients 
and health care systems. Electronic prescribing (e-prescribing) systems have been 
identiﬁ ed as effective tools to improve quality, safety, and efﬁ ciency in health care
delivery. The purpose of this study is to evaluate the effectiveness of a wireless
medication management program in a commercially available e-prescribing system in 
the prevention of serious drug-drug interactions (DDIs). METHODS: This study 
employed a retrospective pre-post with a control group design to evaluate the effective-
ness of wireless handled medication management program in preventing serious DDIs.
A total of 1975 prescribers who received personal digital assistants (PDA) between
August 1, 2004 and June 30, 2005 constituted the technology user group. The com-
parison group included 1063 prescribers who sent a request to obtain, but did not
receive, the technology during the same period. Multivariate regression analysis was 
used to determine if there were differences between the two groups of prescribers in 
the rate of prescribing clinically important DDIs. RESULTS: Prescribers in the two 
groups were signiﬁ cantly different in their specialty practice areas and number of 
pharmacy claims and at baseline. However both groups were similar in their average 
age, profession, and practice type. Prescribers varied in their use of the e-prescribing 
system to access patient medication history, the average number of patient medication 
history updates requested per prescriber in the user group was 42.09 (ranging from 0
to 1073). The most widely prescribed DDIs included those involving warfarin with 
non steroidal anti-inﬂ ammatory drugs (NSAIDs) and anticoagulants with thyroid 
hormones. Compared to the control group, PDA users did not have signiﬁ cantly 
greater decrease in the number of serious potential DDIs as compared to non users
(p  0.65). CONCLUSIONS: The availability of near real-time patient medication
history did not have a signiﬁ cant impact on reducing the rate of prescribing clinically 
important DDIs.
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PRESCRIPTION PATTERNS OF CHINESE HERBAL PRODUCTS 
SUSPECTED OF CONTAINING ARISTOLOCHIC ACID: ANALYSIS OF
REIMBURSEMENT DATA OF A COHORT FROM TAIWAN DURING
1997–2003
Hsieh SC1, Wang JD2
1Center for Drug Evaluation, Taipei City, Taiwan, 2National Taiwan University, College of Public
Health, Taipei, Taiwan
OBJECTIVES: Although the nephrotoxic and carcinogenic effects of Aristolochic
acid (AA) have already been well documented, there is a distinct lack of evidence
on the long-term consumption of Chinese herbal products (CHPs) which either
contain Aristolochia herb species, or which have been adulterated by herbs suspected
of containing AA (SAA herbs). We set out to identify the risks and to determine the 
prescription patterns in Taiwan of CHPs containing SAA herbs (SAA CHPs) prior to 
the promulgation of the regulations banning their use. METHODS: A longitudinal 
analysis was carried out on a randomly sampled cohort of 200,000 patients using
1997–2003 data obtained from the Taiwan National Health Insurance (NHI) reim-
bursement database. RESULTS: During the seven-year study period, a total of 
78,644 patients had been prescribed with SAA CHPs on at least one occasion, the
majority of whom were females and/or middle-aged. A total of 526,867 prescriptions
were issued containing 1,218 licensed SAA CHP items. Over 85% of SAA-exposed 
patients took less than 60 gms of SAA herbs; however, about 7% were exposed to a 
cumulative dose in excess of 100 gms of Xi xin, Mu tong or Ma dou ling. Diseases
of the respiratory and musculoskeletal system were the most common indications 
for the SAA CHP prescriptions. The most frequently prescribed SAA CHPs were 
Shu jing huo xie tang, Chuan qiong cha diao san, and Long dan xie gan tang, respec-
tively containing Fang ji, Xi xin, and Mu tong. CONCLUSIONS: About one-third 
of people in Taiwan have at some time been prescribed with SAA CHPs, and
although the cumulated dosages may not be large, future studies are indicated to 
safeguard CHP usage.
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WHEN COMPARATIVE EVIDENCE IS UNCERTAIN: USE OF
QUANTITATIVE CONSENSUS METHODS TO FILL IN GAPS
Miller RM, Dubois R
Cerner LifeSciences, Beverly Hills, CA, USA
OBJECTIVES: In creating economic models or reimbursement dossiers, gaps in evi-
dence inevitably arise. Typically, these gaps are addressed in a non-systematic and 
non-quantitative manner, leading to inter-expert variability and disagreement amongst
clinicians and decision-makers. The RAND Appropriateness Method is a validated,
structured multi-round Delphi consensus process that we have adapted to US and ex-
US expert panels with broad stakeholders including varying groups of both clinicians 
and payers. We have successfully applied this adapted technique across multiple topics
including diabetes, cancer, depression, and Alzheimer’s disease. METHODS: Partici-
pants reviewed published evidence, guidelines and community practice data and com-
pleted multi-round ratings (9-point scale) with individual and group feedback. Panels
rated (and sometimes ranked) in pre- and post-fashion the likelihood and importance
of selected clinical and/or patient-reported outcomes, as well as the level of scientiﬁ c 
evidence and appropriateness of therapeutic options to address them. Median scores 
and measures of dispersion/disagreement were calculated for each round of ratings.
RESULTS: Utilizing this method consistently resulted in a lower median opinion post-
rating of importance and/or decision categories that are “based on their own experi-
ences or that of their peers” – i.e. a change to more evidence-based decisions rather 
than anecdotal. Additionally, while round 1 ratings often had high disagreement rates
between payers and clinicians or between different treating clinicians, those rates of 
disagreement fell after evidence review and discussion. Moreover, using this method,
payer experts were able to create narrower parameter estimates for the prevalence of 
disease complications and its resulting mortality for use in economic modeling.
Although pre-ratings of value messages were highly variable, payers’ post-evaluation 
ratings after evidence review had less variability and higher (more compelling) scores.
CONCLUSIONS: Use of quantitative consensus processes can minimize idiosyncratic
variation among experts and create a more reliable connection between evidence and 
decision making.
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MEDICATION ADMINISTRATION PROCESS CONDUCTED BY NURSES
IN INTENSIVE AND ACUTE CARE UNITS OF A HOSPITAL: A TIME AND
MOTION STUDY
Dasgupta A1, Sansgiry S2, Frost C3, Tipton J3, Sherer J2
1University of Texas at Austin, Austin, TX, USA, 2University of Houston, Houston, TX, USA, 3St. 
Luke’s Episcopal Hospital, Houston, TX, USA
OBJECTIVES: To determine workﬂ ow variables associated with medication adminis-
tration process conducted by nurses in intensive and acute care units of a hospital. 
METHODS: A time-and-motion study was conducted in intensive and acute care units 
of a hospital. Each medication administration was operationalised as a combination 
of ﬁ ve activities namely direct patient care (ﬁ ve tasks), indirect patient care (four tasks), 
administration (four tasks), miscellaneous (three tasks) and other. Time devoted to 
each medication administration and each task were evaluated by means of two pre-
calibrated stop-watches. Perception of nurses regarding workﬂ ow burden during each 
medication administration was determined on a ﬁ ve point Likert scale as strongly dis-
agree (1)—Strongly agree (5). Furthermore patient features (age, gender, number of 
co-morbidities, length of stay) and complexity of medication administration (frequency 
of each task, number of assistants involved, number of drugs administered through 
different routes) were used to predict medication administration time. Descriptive sta-
tistics were reported. Stepwise regression analysis was performed to examine predictors 
of medication administration time. RESULTS: Mean medication administration time 
in intensive (N  101) and acute (N  100) care units were 5.2 o 3.7 minutes and 5.3 
o 3.5 minutes respectively. Overall nurses had positive perception regarding the sup-
portive workﬂ ow structure of intensive (4.4 o 0.08) and acute care (4.6 o 0.5) units. 
Stepwise regression analysis indicated that signiﬁ cant (p  0.05) predictors of medica-
tion administration time in intensive care unit were time devoted to administration 
(B  0.57), direct patient care (B  0.30), and miscellaneous (B  0.14) activities. Like-
wise signiﬁ cant (p  0.05) predictors of medication administration time in acute
care unit were time devoted to administration activity (B  0.67), gender of patient
(B  0.21) and number of inhaled drugs administered (B  0.16). CONCLUSIONS:
Administration activity played a predominant role during medication administration 
in both units. Measures taken by hospital pharmacy to optimize such an activity may 
result in reduction of workﬂ ow burden encountered by nurses in the units.
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LITERATURE REVIEW OF THE IMPACT OF OBESITY ON
CARDIOVASCULAR OUTCOMES IN THE GENERAL POPULATION AND 
IN PATIENTS WITH TYPE-2 DIABETES
Smith-Palmer J1, Kalsekar A2, Boye KS2, Goodall G1
1IMS Health, Basel, Switzerland, 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: There is an established causal link between obesity and cardiovascular
outcomes. The aim of this review was to determine whether an independent relation-
ship exists between anthropometric measurements of weight (typically body mass
index [BMI]) and cardiovascular outcomes (e.g., angina, myocardial infarction, con-
gestive heart failure, stroke, mortality) in the general population and in patients
with type-2 diabetes. METHODS: A review of the medical literature was conducted
between 1988 and May 2008 using the PubMed, EMBASE, Cochrane and Center for
Review and Dissemination databases. We included studies that were longer than 12 
months, had greater than 500 adult subjects and were written in the English language. 
RESULTS: In studies conducted in general populations there was an overall trend 
towards increased risk for cardiovascular outcomes with increasing BMI. However, a
few studies reported a J-shaped or U-shaped between BMI measurements and cardio-
vascular events. The nature and strength of this relationship varied according to the 
measurement used (e.g., BMI, waist circumference, waist-to-hip ratio) and the popula-
tion studied, with notable differences observed in Asian/Asia-Paciﬁ c based studies 
compared with those conducted in European or North American populations. There
was limited data from prospective, long-term, longitudinal studies examining the 
relationship between degrees of weight and cardiovascular disease in patients with
type-2 diabetes. CONCLUSIONS: In general, the degree of being overweight or obese
Abstracts A97
was associated with an elevated risk of adverse cardiovascular events and mortality.
Although inextricable links exist between obesity, type-2 diabetes and cardiovascular
disease in the general population, the extent to which ﬁ ndings can be extrapolated to 
a diabetes-speciﬁ c population is limited.
PDB2
A1C AND WEIGHT OUTCOMES FOLLOWING 6 MONTHS OF ANALOG
BASAL INSULIN IN INSULIN NAÏVE PATIENTS WITH TYPE-2 DIABETES
IN AN AMBULATORY CARE SETTING
McAdam-Marx C1, Brixner D1, Ye X1, Misurski D2, Fabunmi R3
1University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2Eli Lilly and Company, 
Indianapolis, IN, USA, 3Amylin Pharmaceuticals, Inc., San Diego, CA, USA
OBJECTIVES: This study evaluated real world outcomes for type 2 diabetes (T2D)
patients treated with analog basal insulin (glargine or detemir) on glycemic control and 
weight after 6 months in a national electronic medical record (EMR) database.
METHODS: Patient data were extracted from the General Electric (GE) EMR database 
from January 1, 2000 through December 31, 2007. Patients were q18 years old with 
T2D deﬁ ned by ICD-9 codes, q2 fasting blood glucose levels q126 mg/dL, or A1C 
7.0%. Patients had prescription orders in the previous 395 days for metformin, a sul-
fonylurea or a thiazolidinedione, alone or in combination, or had no prior antidiabetic 
treatment. Patients were initiated on a basal insulin with no prior insulin use, had no
other insulin prescribed within six months of basal insulin initiation, and had at least
one additional order for the prescribed basal insulin within six months. Baseline A1C
and weight were documented a45 days prior to q15 days post basal insulin initiation
and at six months post initiation o 45 days. RESULTS: Of patients with 6 month A1C
or weight follow-up data (n  841 and n  1817, respectively), mean (oSD) baseline 
A1C was 9.0 o 1.9% and weight was 99 o 25.0 kg. Mean BMI was 34.7 o 8.1 kg/m2. 
The majority were treated with insulin glargine (n  1754; 91.2%). At six months mean
(SEM) A1C reduction was 1.2(0.1)% with 20.0% (n  393) achieving A1C goal of 
7.0%;. Mean weight gain was 1.0(0.1) kg (p  .001) and 60% (n  1103) of patients
gained weight. CONCLUSIONS: In a real world setting, most patients (80%) did not
reach ADA targets for glycemic control with analog basal insulin treatment. Addition-
ally, the majority of patients (60%) experienced weight gain.
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EFFECTS OF SUSTAINED-RELEASE VERSUS IMMEDIATE-RELEASE 
GLIPIZIDES FOR TYPE-2 DIABETES MELLITUS: A SYSTEMATIC REVIEW 
OF 16 RANDOMIZED TRIALS
Wang L1, Li Y2
1Sichuan University, Chengdu, Sichuan, China, 2West China Hospital, Sichuan University, 
Chengdu, China
OBJECTIVES: Sustained-release glipizide has a more appealing pharmacological
proﬁ le over immediate-release glipizides. However, individual trials have not reliably 
ascertained its effects. This study systematically reviewed the trials that compared the 
effects of sustained-release glipizide with the conventional immediate-release glipizide 
for type 2 diabetes mellitus. METHODS: We searched Medline, EMBASE, the 
Cochrane Library and three other Chinese databases from their inception to July 2008, 
as well as screened the reference lists of eligible trials and reviews, and contacted the 
company (Pﬁ zer) for unpublished data. Two reviewers judged the trial eligibility,
assessed the validity, and extracted data independently. We pooled the trial data using
the random-effect model and explored the heterogeneity by the pre-speciﬁ ed variables.
RESULTS: A total of 16 trials (n  1033) were included. Sustained-release glipizide 
signiﬁ cantly decreased FPG by 0.33mmol/L (weighted mean difference, 95%CI 0.05
to 0.61), postprandial insulin levels by 3. ìIU/ml (0.89 to 5.47), and C-peptide by 
0.12 ng/ml (0.04 to 0.20). Sustained-release glipizide did not reduced the HbA1c 
(0.02, 0.20 to 0.15), postprandial plasma glucose (0.38, 0.47 to 1.22), fasting 
insulin levels (1.20, 0.14 to 2.54). No statistical differences were found in the change 
of total cholesterol (0.09, 0.06 to 0.23), triglyceride (0.13, 0.04 to 0.29), LDL
(0.03, 0.12 to 0.05), HDL(0.04, 0.02 to 0.10), and hypoglycemia (RR 0.79,
95%CI 0.22 to 2.86). No trials reported diabetes-related morbidity and mortality.
CONCLUSIONS: Sustained-release glipizide could reduce FPG, postprandial insulin
levels, and C-peptide, but has not shown beneﬁ ts in reducing HbA1c, PPG, and fasting 
insulin levels when compared to immediate-release glipizide. Uncertainty remained in
the beneﬁ ts of sustained-release glipizide over immediate-release glipizide. This was 
mainly driven by the small sample size of the trial and lack of long-term morbidity 
and mortality data.
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METFORMIN TREATMENT FOR IMPROVING OUTCOMES RELATED TO
INFERTILITY IN POLYCYSTIC OVARY SYNDROME – A BAYESIAN
ANALYSIS
Perera PN, Malone DC
University of Arizona College of Pharmacy, Tucson, AZ, USA
OBJECTIVES: This study was conducted to determine the usefulness of metformin 
therapy in improving outcomes related to infertility in patients with polycystic ovary 
syndrome (PCOS). A Bayesian meta-analytic and mixed treatment comparison (MTC) 
approach was used. METHODS: An electronic literature search was performed using 
PubMed and the Cochrane Central Register of Controlled Trials to identify random-
ized controlled trials that reported at least one of the outcomes of interest – ovulation,
pregnancy and live birth in PCOS patients randomized to treatment with either met-
formin, clomiphene citrate (CC) or combination of these drugs, which included a 
comparison with either placebo or each other. Reference lists of meta-analyses and 
reviews were hand searched to identify any additional articles. Bayesian meta-analyses 
were conducted for each outcome separately and for different therapeutic comparisons 
with metformin. Additionally, Bayesian MTCs were also conducted for each outcome.
Analyses were performed using random effects models. RESULTS: A total of 27 RCTs
were identiﬁ ed and 24 studies reported outcomes in a usable form for inclusion in the 
analysis. The total number of patients was 2217. The meta-analyses revealed that 
metformin was superior to placebo for ovulation induction (median OR  2.9 with 
95%[CrI] 1.6–6.0). Comparison of metformin and CC to CC alone revealed that
combination therapy was superior in both ovulation induction (median OR  4.2 with 
95%[CrI] 1.5–12.3) and pregnancy (median OR  5.0 with 95%[CrI] 1.7–22.4).
When live birth was considered there was no signiﬁ cant difference between combina-
tion therapy and CC alone (median OR  2.2 with 95%[CrI] 0.4–55.5). In the MTC, 
the efﬁ cacy of the therapeutic comparisons for ovulation and pregnancy in descending 
ranking order was combination therapy, CC alone, metformin alone and placebo.
CONCLUSIONS: Combination therapy with metformin and CC is more effective than 
CC alone in ovulation and pregnancy outcomes in women with PCOS.
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SYSTEMATIC REVIEW IN TYPE-2 DIABETES – WHAT IS THE
INFLUENCE OF LIFESTYLE CHANGE?
Arora A1, Aneja G1, Shukla H1, Alnwick K2
1Heron Health Private Limited, Chandigarh, India, 2Heron Evidence Development Ltd, 
Letchworth Garden City, UK
OBJECTIVES: The aim of this review was to assess whether lifestyle education pro-
grams signiﬁ cantly improve glucose levels or lower the incidence of type-2 diabetes in
people at high risk, compared with conventional education programs. METHODS:
English language trials assessing lifestyle interventions (physical exercise, diet control 
and counselling programs) compared to usual care controls were searched via elec-
tronic databases. Two investigators independently reviewed abstracts and included
studies in which subjects had impaired glucose tolerance, impaired fasting glucose or
borderline values. Data was extracted from each included full-text publication. The 
outcomes of interest included change in glucose levels two hours after a 75g oral
glucose load, change in fasting plasma glucose levels, and cumulative diabetes inci-
dence during the intervention period. RESULTS: Eleven citations met the eligibility 
criteria, out of 198 retrieved from the databases. Of these, only four presented sufﬁ -
cient data for meta-analysis. Meta-analysis of two studies indicated that the decrease 
from baseline in 2-hour plasma glucose was signiﬁ cantly greater in the lifestyle inter-
vention group than in the control group (WMD  11.292 mg/dL, 95% CI: 17.718, 
4.866). Results were similar for fasting plasma glucose, with a ﬁ xed-effects meta-
analyses of data from the same two studies showing a signiﬁ cantly greater decrease
from baseline in the intervention group compared to control (ﬁ xed effects WMD 
2.158 mg/dL, 95% CI: 4.239, 0.077). Meta-analysis of two other studies indicated
that the cumulative diabetes incidence in the lifestyle intervention group was signiﬁ -
cantly lower than in the control group (ﬁ xed effects RR  0.619, 95% CI: 0.522,
0.733). CONCLUSIONS: Structured lifestyle interventions involving a healthy diet 
and physical activity are an effective way to treat, prevent, and possibly delay type-2
diabetes. If lifestyle interventions are cost-effective from a health system perspective,
they should be more frequently considered as a valid treatment option.
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18 MONTH A1C AND WEIGHT OUTCOMES OF EXENATIDE THERAPY
IN PATIENTS WITH TYPE-2 DIABETES IN A REAL-WORLD STUDY
Brixner D1, McAdam-Marx C1, Ye X1, Misurski D2, Wintle M3, Fabunmi R3
1University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2Eli Lilly and Company, 
Indianapolis, IN, USA, 3Amylin Pharmaceuticals, Inc., San Diego, CA, USA
OBJECTIVES: Six-month real-world outcomes were previously reported for exena-
tide, a GLP-1 receptor agonist for the treatment of type- 2 diabetes (T2D). A1C 
reductions were 0.7%, weight reductions were 2.8 kg, and BMI reductions were 
0.94 kg/m2. The current 18 month analysis evaluated A1C, weight, and BMI out-
comes to establish real-world durability of glycemic control and weight loss in patients 
using exenatide. METHODS: Data were extracted from the General Electric electronic 
medical record database from January 1, 2000 to December 31, 2007. Adults with
T2D per ICD-9 codes, q2 fasting blood glucose levels q126 mg/dL, or A1C  7.0% 
starting exenatide in or after 2005 were included. Patients had 2 additional prescrip-
tion orders including at least one 12 to 18 months after the initial prescription to 
indicate ongoing therapy, and had prior prescription orders for metformin, a sulfo-
nylurea, or a thiazolidinedione alone or in combination. A1C, weight and BMI were
documented at exenatide initiation (45 to  15d) and at 18 months (o45 d). Out-
comes were evaluated in those with baseline and follow-up A1C, weight and BMI
measures. RESULTS: In 102 study patients, baseline A1C was 8.21.1%, weight was
111 o 12.3 kg. Baseline BMI was 38.6q o 7.4 kg/m2 in those with baseline and follow 
up data (n  89). After 18 months of exenatide therapy, mean (oSEM) A1C decrease 
was 0.7(o0.2)% (p  .001), weight decrease was 4.7(o0.7) kg (p  .001), and BMI 
decrease was 0.8 (o0.3) kg/m2 (p  .001). A total of 72.0% had an A1C reduction, 
76.7% lost weight, and 57.0% had reductions in A1C and weight. Mean A1C reduc-
tion was identical and weight loss was approximately 2 kg greater at 18 months rela-
tive to 6 month cohort exenatide outcomes. CONCLUSIONS: Exenatide therapy was 
associated with signiﬁ cant reductions in A1C, weight and BMI at 18 months. These 
reductions demonstrate treatment durability with exenatide and continuous beneﬁ t 
from long term therapy.
